Moreover, the possibility to use Glu–Ocn as a prognostic or pathogenic marker for metabolic–endocrine disorders remains to be confirmed since no universal standardized method exists for its measurements; osteocalcin should be evaluated by HA binding assay, by electro-chemiluminiscence immunoassay, or by ELISA. The gene discussed is BGLAP; the disease is endocrine system disorder.